Arca
Skip to content
Tools
Tools

-rafenib

A RAF kinase inhibitor, blocking a link in the MAPK growth-signal chain; used in melanoma and other cancers with BRAF mutations.

  • Drugs ending in -rafenib: 17
  • Approved somewhere: 6
  • With a US drug page: 6

What it means

Stem from WHO's stem book, 2024; description by Arca
Stem
-rafenib
Class
Drugs that block RAF kinases, like sorafenib

Drugs that carry it

Approved and clinical-stage drugs in ChEMBL whose names ending in -rafenib, matched by spelling; those with a US drug page link to it.
Acts on
DabrafenibApprovedBRAFSerine/threonine-protein kinase B-raf inhibitor
EncorafenibApprovedBRAFSerine/threonine-protein kinase B-raf inhibitor
RegorafenibApprovedABL1, RAF1, KIT, FGFR1 and 11 moreTyrosine-protein kinase ABL inhibitor
SorafenibApprovedRAF1, PDGFRB, KIT, FLT3 and 3 moreSerine/threonine-protein kinase RAF inhibitor
TovorafenibApprovedRAF serine/threonine protein kinaseRAF serine/threonine protein kinase inhibitor
VemurafenibApprovedBRAFSerine/threonine-protein kinase B-raf inhibitor
NaporafenibPhase 3BRAF, RAF1B-raf/RAF proto-oncogene serine/threonine-protein kinase inhibitor
BelvarafenibPhase 2RAF serine/threonine protein kinaseRAF serine/threonine protein kinase inhibitor
BrimarafenibPhase 2——
ExarafenibPhase 2——
FlezurafenibPhase 2——
MosperafenibPhase 2——
PlixorafenibPhase 2BRAFSerine/threonine-protein kinase B-raf inhibitor
UplarafenibPhase 2——
ClaturafenibPhase 1——
LifirafenibPhase 1BRAFSerine/threonine-protein kinase B-raf inhibitor
TinlorafenibPhase 1——

Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.